Dingdang Health Technology Group Ltd. (Dingdang Health) reported a minor adjustment to its share capital following a repurchase executed on 14 September 2026.
On-market transaction • Volume: 17,500 ordinary shares repurchased for treasury holding • Price range: HKD 0.80–0.835 per share • Volume-weighted average cost: HKD 0.8314 per share • Total consideration: HKD 0.01 million (HKD 14,550.25)
Capital structure post-transaction (14 September 2026) • Issued shares (excluding treasury): 1.23594 billion, down 17,500 shares from 11 September • Treasury shares: 4.37 million, up from 4.35 million • Total issued shares (including treasury): unchanged at 1.24031 billion • Repurchased amount represents 0.0014 % of outstanding shares before the buyback.
Repurchase mandate utilisation • Shareholders’ mandate granted on 23 June 2026 authorises buybacks of up to 124.32 million shares. • Cumulative repurchases under the mandate now total 7.23 million shares, equivalent to 0.58 % of the company’s outstanding shares as at mandate date.
Regulatory position and next steps • The company affirmed compliance with all Hong Kong Stock Exchange listing rules and relevant legal requirements. • In line with HKEX rules, Dingdang Health is subject to a 30-day moratorium on new share issues or treasury-share disposals, effective until 14 October 2026.
No shares repurchased under this transaction have been cancelled; all are held as treasury shares.
Comments